Orion - Annual report/ annual accounts

Orion Group Annual Report 2011 published

ORION CORPORATION        STOCK EXCHANGE RELEASE 6 March 2012 AT 11.35  EET


Orion Group's Annual Report for 2011 has been published. The report is available
in Finnish at http://ar2011.orion.fi and in English at
http://ar2011.orion.fi/en. The Annual Report 2011 is published only as an Online
Report.

Orion's Corporate Governance Statement for year 2011, adopted by the Board of
Directors, is published as a separate report in Finnish at
http://www.orion.fi/en/Orion/Corporate-Governance/ and in English at
http://www.orion.fi/en/Orion/Corporate-Governance/.




Orion Corporation



Olli Huotari              Terhi Ormio
SVP, Corporate Functions  VP, Communications




Attached PDF version:

Orion Corporate Governance Statement 2011.pdf


Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi



Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, oncology and critical care drugs, and Easyhaler(®)
pulmonary drugs.

The Group's net sales in 2011 amounted to EUR 918 million. The Company invested
EUR 88 million in research and development. At the end of 2011, the Group had
about 3,400 employees, of whom about 2,700 worked in Finland and the rest in
other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.


[HUG#1591505]

Attachments:

Orion Corporate Governance Statement 2011.pdf